Oncocross Co.,Ltd.
Founded in 2015, Oncocross provides the disease-drug matching AI platform RAPTOR AI and the oncology-specialized ONCO-RAPTOR AI.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KOSDAQ in 2024, Oncocross is an AI drug discovery platform company. It offers the transcriptome/proteome-based disease-drug matching platform RAPTOR AI (v2.0), the proteomics analysis service Neo Omics, the oncology-specialized ONCO-RAPTOR AI, and ONCOfind AI, an early cancer diagnosis aid still under development. RAPTOR AI draws on a database of about 500 disease cohorts and roughly 25,000 compounds to provide indication-selection and indication-expansion analysis services that generate revenue, supported by two in-house research institutes -- the Bio Research Institute (established August 2015) and the AI Research Institute (established December 2019).
Products & technology
- RAPTOR AITranscriptome/proteome-based disease-drug matching and optimal indication/combination drug screening (v2.0 extends to ADC and TPD modalities)
- ONCO-RAPTOR AITranscriptome-based prediction of cancer-type specificity and companion diagnostic markers for anticancer drugs
- ONCOfind AIAid for early cancer diagnosis and site-of-origin detection
- Neo OmicsB2B proteomics analysis service supporting drug mechanism understanding and biomarker discovery
R&D and key agreements
Source: DART corporate disclosureRAPTOR AI v2.0 고도화 · Expansion to multi-omics (genome-transcriptome-proteome) analysis, including new modalities such as ADC and TPD
Digital Bio Banking · Pursuing MOUs with major domestic hospitals and building digitized clinical data and cohorts
Companies in the same categoryMedical AI
Founded in 2009, SEERS provides the wearable ECG analysis solution mobiCARE and the inpatient monitoring solution thynC, based on AI vital-sign analytics.
Founded in 2009, SyntekaBio provides genomic big data-based AI drug discovery platforms DeepMatcher and NEO-ARS, along with the NGS-ARS precision medicine service.
Founded in 2008 and listed on KOSDAQ in 2021, DEEPNOID develops medical and industrial AI imaging solutions like DEEP:NEURO.
Founded in 2014, VUNO provides AI-based vital-sign and medical imaging diagnostic solutions, including VUNO Med-DeepCARS and VUNO Med-Fundus AI.
Founded in 2012, Coreline Soft provides the AI-based chest CT diagnostic aid suite AVIEW for lung nodules, COPD, and coronary calcification.
JLK offers the stroke AI solution MEDIHUB STROKE and holds 78 global regulatory approvals, including US FDA and Japan PMDA clearances.
Founded in 2013, Lunit provides AI-driven cancer screening and oncology solutions through Lunit INSIGHT and Lunit SCOPE.
SELVAS AI provides voice and language AI technologies through its HCI and AI Digital Transformation business units.
Founded in 2002, INFINITT Healthcare provides PACS-centered medical imaging software and AI diagnostic aids across multiple clinical specialties.
Founded in 2001, ezCaretech provides the hospital information systems BESTCare (on-premise) and EDGE&NEXT (cloud-based).
Founded in 1985, BITComputer provides hospital information systems such as bitnixHIS and CLEMR, alongside digital healthcare and IT education businesses.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition